Dimensional Fund Advisors LP Sells 68,739 Shares of Dr. Reddy’s Laboratories Ltd (RDY)

Dimensional Fund Advisors LP decreased its position in Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 10.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 569,576 shares of the company’s stock after selling 68,739 shares during the period. Dimensional Fund Advisors LP owned 0.34% of Dr. Reddy’s Laboratories worth $22,878,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Sei Investments Co. raised its position in shares of Dr. Reddy’s Laboratories by 6.0% in the first quarter. Sei Investments Co. now owns 164,816 shares of the company’s stock worth $6,617,000 after buying an additional 9,400 shares during the period. Karp Capital Management Corp acquired a new position in Dr. Reddy’s Laboratories during the first quarter valued at $5,893,000. Wetherby Asset Management Inc. increased its stake in Dr. Reddy’s Laboratories by 9.1% in the first quarter. Wetherby Asset Management Inc. now owns 8,487 shares of the company’s stock valued at $340,000 after buying an additional 711 shares during the period. US Bancorp DE increased its stake in Dr. Reddy’s Laboratories by 12.7% in the first quarter. US Bancorp DE now owns 84,723 shares of the company’s stock valued at $3,402,000 after buying an additional 9,538 shares during the period. Finally, Oxford Asset Management increased its stake in Dr. Reddy’s Laboratories by 98.6% in the first quarter. Oxford Asset Management now owns 47,144 shares of the company’s stock valued at $1,893,000 after buying an additional 23,409 shares during the period. 15.25% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Ltd (NYSE RDY) traded down 0.23% during mid-day trading on Friday, hitting $30.75. 171,222 shares of the company were exchanged. The company has a 50 day moving average of $37.81 and a 200 day moving average of $40.55. The stock has a market cap of $5.10 billion, a P/E ratio of 28.68 and a beta of 0.33. Dr. Reddy’s Laboratories Ltd has a 12-month low of $30.22 and a 12-month high of $50.10.

The firm also recently declared a None dividend, which was paid on Thursday, August 10th. Shareholders of record on Monday, July 17th were issued a dividend of $0.294 per share. The ex-dividend date was Thursday, July 13th. Dr. Reddy’s Laboratories’s payout ratio is 27.88%.

WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/08/19/dr-reddys-laboratories-ltd-rdy-shares-sold-by-dimensional-fund-advisors-lp-updated.html.

Several research firms recently issued reports on RDY. BidaskClub downgraded shares of Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Zacks Investment Research raised shares of Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, July 14th. Deutsche Bank AG raised shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Monday, May 15th. Finally, CLSA lowered shares of Dr. Reddy’s Laboratories from an “underperform” rating to a “sell” rating in a research note on Friday, July 28th. Two research analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. The company has an average rating of “Hold”.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Institutional Ownership by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

What are top analysts saying about Dr. Reddy's Laboratories Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dr. Reddy's Laboratories Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit